Denis Péré-Vergé

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.8K citations · Full text

Medicine, Oncology, Pharmacology +13

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Florence Castan, Anthony Lopez et al. · JAMA Oncology · 2022 · 324 citations · Full text

Medicine, Oncology, Surgery +14

Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study

Marie Selvy, Bruno Pereira, Nicolas Kerckhove et al. · Journal of Clinical Medicine · 2020 · 69 citations · Full text

Medicine, Oncology, Pharmacology +13

Totally implantable central venous access port infections in patients with digestive cancer: Incidence and risk factors

Abdoulaye Touré, Philippe Vanhems, Catherine Lombard‐Bohas et al. · American Journal of Infection Control · 2012 · 48 citations

Medicine, Oncology, Surgery +14

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Thomas Aparicio, Michel Ducreux, Roger Faroux et al. · European Journal of Cancer · 2018 · 46 citations · Full text

Medicine, Nutrition, Oncology +9